



Progression of Liver Diseases

Miriam Liliana Cuarterolo ^{1*}

¹ Hepatology Unit, Hepatology Hospital de Pediatría Juan P. Garrahan, Buenos Aires, Argentina

ARTICLE INFO

Article type:
Letter to Editor

Article history:
Received: 16 May 2012
Revised: 26 May 2012
Accepted: 06 Jun 2012

Keywords:
Liver
Disease
Hepatitis C

► Please cite this paper as:

Cuarterolo ML. Progression of Liver Diseases. *Hepat Mon.* 2012;12(6): 415-6. DOI: 10.5812/hepatmon.6626

Copyright © 2012 Kowsar Corp. All rights reserved.

Dear Editor,

To date, the knowledge on the natural history of HCV infection and the risk factors associated with progression of liver disease in children is limited. Progressive liver disease, including hepatocellular carcinoma, is rare but has been reported (1). Early effective treatment can prevent potential hepatic complications in later life. The association of Peg-IFN plus ribavirin is the option of choice for the treatment of HCV infection in children (2). Patients treated with this therapeutic scheme showed a sustained virological response (SVR) rate of 65 %, being genotype the main predictor of treatment outcome (53 %, 93 %, 93 %, and 80 % with genotype 1, 2, 3, and 4, respectively (3). Several important factors, such as genotype except genotype 1 and low pretreatment serum HCV RNA levels, are associated with favorable therapeutic response. Rapid virological response and early virological response are strong predictors of treatment outcome in genotype 1 patients (3). Mild fibrosis, present in the biopsy of the majority of children with this infection, may also contribute to higher rates of SVR. Adverse effects, particularly those related to mild leukopenia, neutropenia, and thrombocytopenia, are frequently observed during

treatment (2). Low hemoglobin levels may be resulted from ribavirin-induced hemolysis or from IFN-induced bone marrow suppression. Sulkowski *et al.* (4) have recently showed in a large retrospective study, that in treatment of naïve HCV genotype 1 adult patients treated with Peg-IFN plus ribavirin, patients with early-onset anemia (\leq eight weeks of treatment) had higher SVR rates with erythropoiesis-stimulating agents, whereas no effect was observed in whom with late-onset anemia.

Similar results were obtained by Sievert *et al.* (5). They found that in patients with HCV genotype 1 infection, the odds for achieving SVR for those whom lowest hemoglobin was < 100 g/l or whom maximum hemoglobin decline was 30 g/L, were about twice the odds of those whom maximum hemoglobin decline was ≤ 30 g/L or those whom lowest hemoglobin during treatment was ≥ 100 g/L. The mechanisms underlying the higher SVR rates in patients with a decline in hemoglobin remain unclear. The article published by Malgorzata *et al.* is of great interest because of its focus on the relationship between the hematological adverse effects and the response to therapy in children with chronic hepatitis C. 170 patients were included in the study and divided into two groups according to the treatment scheme. Group I (n: 119) received recombinant IFN- α -2b plus RBV and group II (n: 51) was administered peg- IFN- α -2b plus ribavirin. Both groups were treated with a 48-week course. Hematological growth factors and erythropoietin were not used. The authors showed a better response to treatment in terms

* Corresponding author: Miriam Liliana Cuarterolo, Hepatology Unit, Hepatology Hospital de Pediatría Juan P. Garrahan, Buenos Aires, Argentina. Tel: +54-114308430, Fax: +54-114308430, E-mail: mcuarterolo@intramed.net

of obtaining SVR in those patients who presented more hematological adverse effects. With ongoing research, such as this study by Malgorzata *et al.*, investigating markers of response to treatment, great advances can be made for children who will be infected with HCV over the next several years.

Authors' Contribution

None declared.

Financial Disclosure

None declared.

References

1. Gonzalez-Peralta RP, Langham MR, Jr., Andres JM, Mohan P, Colombani PM, Alford MK, et al. Hepatocellular carcinoma in 2 young adolescents with chronic hepatitis C. *J Pediatr Gastroenterol Nutr.* 2009;**48**(5):630-5.
2. Wirth S, Kelly D, Sokal E, Socha P, Mieli-Vergani G, Dhawan A, et al. Guidance for clinical trials for children and adolescents with chronic hepatitis C. *J Pediatr Gastroenterol Nutr.* 2011;**52**(2):233-7.
3. Wirth S, Ribes-Koninckx C, Calzado MA, Bortolotti F, Zancan L, Jara P, et al. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. *J Hepatol.* 2010;**52**(4):501-7.
4. Sulkowski MS, Shiffman ML, Afdhal NH, Reddy KR, McCone J, Lee WM, et al. Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. *Gastroenterology.* 2010;**139**(5):1602-11, 11 e1.
5. Sievert W, Dore GJ, McCaughan GW, Yoshihara M, Crawford DH, Cheng W, et al. Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1. *Hepatology.* 2011;**53**(4):1109-17.